Paper Details

  1. Home
  2. Paper Details

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.

Author: ObergKjell

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Somatostatin analogs are a cornerstone in the treatment of neuroendocrine tumors (NETs), effectively managing hormone-related symptoms and stabilizing tumor growth.
Paper Details　
Original Abstract of the Article :
Neuroendocrine tumors (NETs) are considered to be rare but, during the last two decades, their incidence and prevalence has considerably increased in gastro-entero-pancreatic (GEP) NETs. Most GEP-NETs express somatostatin receptors, which could be targets for treatment. The development of somatostat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/era.09.26

データ提供：米国国立医学図書館（NLM）

The Role of Somatostatin Analog Octreotide LAR in Gastro-Entero-Pancreatic Tumors

This research explores the use of somatostatin analog octreotide LAR in the management of gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs). The study highlights the critical role of somatostatin receptors in these tumors and the potential of somatostatin analogs to target these receptors for therapeutic benefit. The study emphasizes the development of long-acting octreotide LAR as a significant advancement in the treatment of functioning NETs, improving quality of life by reducing the need for frequent injections. The study also acknowledges the potential of combining somatostatin analogs with other biological therapies in the future.

Targeting Somatostatin Receptors in GEP NETs

This study underscores the importance of understanding the role of somatostatin receptors in GEP NETs. The study highlights the potential of somatostatin analogs to effectively target these receptors and provides evidence for the efficacy of octreotide LAR in managing hormone-related symptoms associated with functioning NETs.

Hope for Individuals with GEP NETs

This research offers a glimmer of hope for individuals diagnosed with GEP NETs, providing a comprehensive overview of the potential benefits of somatostatin analog therapy. The study's findings emphasize the importance of ongoing research to develop new and improved treatments for this complex and often challenging condition. Just as a camel relies on its intuition to navigate the vast and unforgiving desert landscape, individuals with GEP NETs rely on medical advancements to navigate the challenges of their condition.

Dr. Camel's Conclusion

This study highlights the ongoing quest to improve the lives of individuals with GEP NETs. The development of somatostatin analogs, particularly long-acting formulations, represents a significant advancement in the management of this condition. We must continue to explore new and innovative treatments to offer hope and support to those living with GEP NETs.

Date :
  1. Date Completed 2009-08-06
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

19445573

DOI: Digital Object Identifier

10.1586/era.09.26

Related Literature

Article Analysis
・Side Effects of pasireotide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.